At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Mathias Rummel presented long-term results from a multicenter Phase III study showing that initial combination chemotherapy with bendamustine and rituximab more than doubled progression-free survival.